-Have an acute illness within 72 hours prior to study vaccination. -Any medical disease or condition that, in the opinion of the investigator, is a contraindication to study participation. -Note: Includes medical disease or condition that would place the subject at an unacceptable risk of injury, render them unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or their successful completion of the study. -Have history of any significant acute or chronic medical conditions or need for chronic medications that, in the opinion of the investigator, will interfere with immunogenicity or affect safety. -Note: Chronic medical condition - a medical condition persisting 3 months (defined as 90 days) or longer -Have immunosuppression or are taking systemic immunosuppressants as a result of an underlying illness or treatment. -Diagnosis of asthma or reactive airway disease within the past 2 years. -History of surgical splenectomy. -Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 36 months prior to vaccination. -Have known active neoplastic disease or a history of any hematologic malignancy. -Have known hepatitis B or hepatitis C infection. -Have known hypersensitivity or allergy to eggs, egg or chicken protein, squalene-based adjuvants, or other components of the study vaccine. -Known allergy or intolerance to oseltamivir. -Have a history of severe reactions following previous immunization with licensed or unlicensed influenza virus vaccines. -Have a history of Guillain-Barré Syndrome. -Have a history of neuralgia, paresthesia, neuritis, convulsions, or encephalomyelitis within 90 days prior to study vaccination. -Have a history of autoimmune disease. -Note: Including, but not limited to, neuroinflammatory diseases, vasculitis, clotting disorders, dermatitis, arthritis, thyroiditis, or muscle, liver, or kidney disease. -Have a history of alcohol or drug abuse within 5 years prior to study vaccination. -Have any diagnosis, current or past, of schizophrenia, bipolar disease, or other psychiatric diagnosis that may interfere with subject compliance or safety evaluations. -Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 10 years prior to study vaccination. -Have taken oral or parenteral corticosteroids of any dose within 30 days prior to study vaccination. -Chronic use (defined as daily use for > 7days within the 30 days prior to study vaccination) of any inhaled medication, including inhaled corticosteroids. -Received any licensed live vaccine within 30 days prior to pIIV vaccination. This is inclusive of licensed seasonal influenza vaccines. -Received any licensed inactivated vaccine within 14 days prior to pIIV vaccination. This is inclusive of licensed seasonal influenza vaccines. -Planned receipt of any vaccine from the first study vaccination through the follow-up visit at approximately 56 days after the second study vaccination. This is inclusive of licensed seasonal influenza vaccines -Received immunoglobulin or other blood products (with exception of Rho D immunoglobulin) within 90 days prior to study vaccination. -Received an experimental agent within 30 days prior to pIIV administration or planned receipt of an experimental agent to within 90 days after pLAIV administration. -Note: Includes vaccine, drug, biologic, device, blood product, or medication. - Plans to enroll in another clinical trial that could interfere with safety assessment of the investigational product at any time during the study period. -Note: Includes trials that have a study interven tion such as a drug, biologic, or device -Prior participation in a clinical trial of influenza A/H7 vaccine or have a history of A/H7 actual or potential exposure or infection prior to the first study vaccination. -Note: Documented receipt of placebo in such a trial is not exclusionary -Plan to travel outside the U.S. (continental U.S., Hawaii and Alaska) in the time between the first study vaccination and 56 days after the second study vaccination. -Positive screening pregnancy test or other evidence of pregnancy.-Female subjects who are breastfeeding or plan to breastfeed at any given time from the first study vaccination until 30 days after their last study vaccination. -Seropositive to the H7N9 influenza A virus (serum HAI titer >1:8) during the screening period prior to the first study vaccination. -Positive urine drug screen for opiates and cocaine at the time of check-in for the period of confinement. -Positive ELISA and confirmatory Western blot tests for human immunodeficiency virus-1 (HIV-1) during the screening period prior to vaccination. -Current smoker unwilling to stop smoking for the period of confinement. A nicotine patch during the period of confinement may be offered.